ShihYTGanzPAAberleDet al.Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol2013; 31: 4151–4157.
2.
MeropolNJSchulmanKA. Cost of cancer care: issues and implications. J Clin Oncol2007; 25: 180–186.
3.
HowardDHBachPBBerndtERet al.Pricing in the market for anticancer drugs. J Econ Perspect2015; 29: 139–162.
4.
SiddiquiMRajkumarSV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc2012; 87: 935–943.
5.
AngellM. Excess in the pharmaceutical industry. CMAJ2004; 171: 1451–1453.
6.
GilbarPJ. Should the pharmaceutical industry be doing more to reduce the cost of cancer drugs?J Pharm Prac Res2011; 41: 4–5.
7.
BachPBContiRMMullerRJet al.Overspending driven by oversized single dose vials of cancer drugs. BMJ2016; 352: i788–i788.
8.
Gilbar PJ, Chambers CR and Gilbar EC. Opportunities to significantly reduce expenditure associated with cancer drugs. Future Oncol. [in press] 2017.
9.
PearsonSARinglandCLWardRL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia – monitoring the effect of an expensive medicine access program. J Clin Oncol2007; 25: 3688–3693.
10.
BenziriFBonanBFerrioALet al.Stability of antineoplastic agents in use for home-based intravenous chemotherapy. Pharm World Sci2009; 31: 1–13.
11.
De LemosMLHamataL. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract2007; 13: 27–31.
12.
BardinCAstierAVultoAet al.Guidelines for the practical stability studies of anticancer drugs: a European consensus conference. Ann Pharm Fr2011; 69: 221–231.
13.
AlexanderMKingJBajelAet al.Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel. Intern Med J2014; 44: 1018–1026.
14.
KingJAlexanderMByrneJet al.A review for the evidence for occupational exposure risks to novel anticancer agents – a focus on monoclonal antibodies. J Oncol Pharm Pract2016; 22: 121–134.
15.
SmithRSV. A 2-year retrospective review of vial sharing options for the compounding of cytotoxics. Eur J Hosp Pharm2015; 22: 161–164.
16.
EdwardsMSSolimandoDAJrGrollmanFRet al.Cost savings realized by use of the PhaSeal® closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract2013; 19: 338–347.
17.
JuhaszABatkaGSzucsA. Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs Ther Perspect2016; 32: 170–176.
18.
LienKCheungMCChanKKW. Adjusting for drug wastage in economic valuations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract2016; 12: e369–379.
19.
DooleyMJSinghSMichaelM. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer2004; 12: 653–656.
20.
FieldKZelenkoAKosmiderSet al.Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia-Pac J Clin Oncol2010; 6: 203–209.
PlumridgeRJSewellGJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health-Syst Pharm2001; 58: 1760–1764.
23.
ChatelutEWhite-KonigMLMathijssenRHJet al.Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer2012; 107: 1100–1106.
